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Chemotherapy drugs, such as 5-fluorouracil (5FU), are the standard approach for cancer and are associated with several peripheral
toxicities.We previously demonstrated thatMuricidaemarinemolluscs exhibit chemopreventive properties.This study investigated
the combined effect of muricid extract derived from Dicathais orbita, with 5FU, on intestinal toxicity in rats. Groups of rats were
orally gavaged water, muricid extract, or sunflower oil, with or without 5FU (150mg/kg). Metabolic data was collected daily and
small intestinal brush border enzyme activity was measured by sucrose breath test (SBT). Blood was collected by cardiac puncture
for whole blood analysis. Intestinal biopsies were taken for histopathology. Neutrophil activity was measured by myeloperoxidase
activity. No additional toxicity effects were observed in rats receiving the combination of 5FU and muricid extract compared to
5FU alone, as indicated by SBT, histopathology, and myeloperoxidase activity. Intestinal integrity was protected from 5FU-induced
damage in the sunflower oil vehicle group, compared to controls, as measured by SBT, villus height, and crypt depth.We concluded
that combination of muricid extract and 5FU did not confer any additional intestinal toxicity, further supporting its potential as a
chemopreventive food product. In this model system, sunflower oil partially protected against 5FU-induced intestinal toxicity.
1. Introduction
Colorectal cancer (CRC) is the second most common malig-
nancy in the world and has the second highest mortality rate
of all cancers [1]. Pathogenesis is initiated by the formation
of aberrant crypt foci, mucosal cell clusters, polyps, adeno-
mas, and adenocarcinoma [1]. Treatment with 5-fluorouracil
(5FU) and leucovorin (folinic acid) is the mainstay of therapy
for patients with stage III and selected stage II CRC [2]. How-
ever, cytotoxic drugs, such as 5FU, are commonly associated
with significant peripheral toxicities arising from off-target
specificity, targeting all rapidly dividing cells, particularly the
gastrointestinal epithelia.
Clinically referred to as mucositis, it affects 40% of
patients after standard doses of chemotherapy and up to
100% of patients undergoing high dose chemotherapy for
hematopoietic stem cell transplantation, or radiation for head
and neck cancers [3]. Symptoms of mucositis include, but
are not limited to, dysphagia, ulceration, bleeding, abdominal
pain, and diarrhoea [3]. Furthermore, the damaged intesti-
nal barrier may allow for the translocation of pathogens,
leading to life-threatening complications with septicemia [4].
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These dose-limiting and potentially life-threatening symp-
toms impact patient quality of life but also lead to a significant
economic burden on health care systems [3]. Novel thera-
peutic agents possessing chemopreventive properties, with
limited or no gastrointestinal toxicities, are urgently required.
Recently, natural food products have emerged as potential
chemopreventive agents for a range of different cancer types
[5–8].Wehave recently identifiedMuricidaemarinemolluscs
as a source of natural brominated indole derivatives with
potential chemopreventive properties [9]. At relatively high
concentration, crudemuricid extracts derived fromDicathais
orbita, containing a mixture of 6-bromoisatin and tyrindole-
ninone (6-bromo-2-methylthio-3H-indol-3-one), were found
to inhibit the growth of a range of solid tumour and lym-
phoma cell lines [10, 11]. In particular, these molluscs extracts
reduced the viability of the HT29 and Caco2 colon carci-
noma cell lines by over 70% and 80%, respectively in vitro
[10]. Semipurified extracts containing tyrindoleninone were
cytotoxic towards Caco2 cells (IC
50
= 98 𝜇M), and HT29
(IC
50
= 390 𝜇M), whereas 6-bromoisatin induced cell death
by apoptosis in both cell lines at approximately 100 𝜇M [9].
Furthermore, in mice with azoxymethane induced CRC,
prophylactic oral administration of high dose (1mg/g) muri-
cid extract, containing these brominated indoles, displayed
significantly higher rates of apoptosis in the distal colon
relative to control mice [12]. The purple dye secretion from
muricid molluscs also contains the minor pigment 6,6󸀠
dibromoindirubin [13], which has been identified as a potent
protein kinase inhibitor [14–16]. These indirubin derivatives
have been shown to induce apoptosis in human cancer cells
[17–19]. Furthermore, indirubin has been shown to have
inhibitory effects on the production of interferon-𝛾 and
to suppress inflammatory reactions in delayed type hyper-
sensitivity in mice [20]. Thus, Muricidae derived products
represent potential chemotherapeutic or chemopreventive
reagents.
In many cultures, marine molluscs, including Muricidae
whelks, are regarded as a healthy food, featuring in a range of
traditional natural remedies [9]. Muricidae molluscs form a
traditional component of some African, European, Mediter-
ranean, and Asian diets [21–23], indicating their tolerability
for human consumption. Nevertheless, the potential for
toxicity associated with a concentrated bioactive extract from
these molluscs requires further consideration.
Our preliminary studies of a Muricidae extract indicated
the potential for mild, idiosyncratic effects on the liver and
gastrointestinal tract in a small proportion of mice [24]. Fur-
thermore, it is likely that, in clinical use, the extracts would
be used as an adjunct to traditional chemotherapy agents,
aimed at lowering cytotoxic doses and in turn harmful side-
effects, primarily mucositis. The current study aimed to
define the potential toxicity effects of muricid extract in rats,
when administered alone, or in combination with 5FU.
2. Methods
2.1. Preparation and Analysis of Extract. Frozen Dicathais
orbita were cracked in a vice, to allow removal of the shell
and access to the hypobranchial glands, which were excised
for extraction according toWestley et al. [12]. Hypobranchial
glands were extracted by soaking in AR grade chloroform
and methanol (1 : 1, v/v, Selby-Biolab, Pronalys, Melbourne,
VIC, Australia) under agitation at 4∘C for 2 h in a dark room,
followed by overnight soaking in fresh solvent and a final 2 hr
extraction.Milli Q water was used to induce the separation of
the chloroform layer from themore polar compounds and the
chloroform extract was dried by rotary evaporation at 40∘C in
a quickfit flask covered with alfoil to exclude light.The extract
was then transferred to preweighed amber vials and dried
under a stream of high purity N
2
gas and stored at −80∘C
until use. Extract was dissolved in sunflower oil to facilitate
oral administration.
The extract was analyzed using liquid chromatography
coupled with mass spectrometry (LC/MS) using the pro-
cedures previously established in our laboratory [25]. The
extract was dissolved in acetonitrile and analyzed by HPLC
(Waters Alliance) on a Hydro-RP C18 column, coupled
to an electrospray ionization mass spectrometer (ESI MS,
Micromass, Quatromicro), with parallel UV/Vis diode-array
detection at 300 and 600 nm. Mass Lynx 4.0 software was
used to analyze the data. The relative percent composition of
brominated indoles was calculated from the integrated area
under the curve for the intensity (absorbance units) of each
peak at 300 nm.
2.2. Animal Studies. Female dark agouti rats, sourced from
the University of Adelaide (𝑛 = 72), were housed in indi-
vidual metabolism cages (Tecniplast, PA, USA), in a temper-
ature-controlled room with a 12-hour light/dark cycle. Ani-
mals were allowed ad libitum access to water and food (18%
weight maintenance casein diet). 1mL of water or extract
dissolved in sunflower oil was administered daily via orogas-
tric gavage between −72 and 72 hours of the experimental
period. At 0 hours, all rats were administered a single dose of
either saline or 5-fluorouracil (150mg/kg;Mayne Pharma Pty
Ltd, VIC, Australia) via intraperitoneal injection. Rats were
randomly allocated to one of eight groups (𝑛 = 8): Saline
injection groups were administered either water, sunflower
oil, 0.1mg/g crude extract (low dose (LD)), or 0.5mg/g
crude extract (high dose (HD)), and 5FU injection groups
were administered either water, sunflower oil, 0.1mg/g crude
extract, or 0.5mg/g crude extract. The 5FU dark agouti rat
model of mucositis has been well established [26] and was
selected for its resemblance to the physiologicalmanifestation
of chemotherapy induced toxicity in humans. This study was
carried out in strict accordance with the recommendations
of the Australian Code of Practice for the Care and Use of
Animals for Scientific Purposes. The protocol was approved
by the animal ethics committee of the Children, Youth and
Women’s Health Service (approval number AE700/3/2010).
Rats were monitored daily and metabolic indices includ-
ing food and water intake, urine and fecal output, and
bodyweight were recorded. Furthermore, stool consistency
was monitored daily and scored according to a diarrhoea
index, where 0 = well-formed stools to 3 = watery stools.
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Rats were killed by CO
2
overdose and cervical dislocation 72
hours after saline or 5FU injection.
2.3. 13C-Sucrose Breath Test. The 13C-sucrose breath test
(SBT) was performed to assess small intestinal disaccharidase
activity in vivo [27]. The SBT was performed prior to the
commencement of the trial (−72 hours before 5FU/saline),
prior to saline or 5FU injection (0 hours), and prior to
sacrifice (72 hours after 5FU/saline injection). Animals were
fasted overnight, before being gavagedwith 1mL of 0.25 g/mL
sucrose solution, labeled with 13C. They were then placed
in sealed perspex containers for 2 minutes, before a 20mL
sample of breath was collected into an evacuated tube. Breath
samples were collected at 0, 15, 30, 45, 60, 75, 90, 105, and
120 minutes after administration of the sucrose solution.
The samples were analysed for 13C by an isotope ratio mass
spectrometer, as described by Howarth et al. [27], and all
data was expressed as a % cumulative dose at 90 minutes
(%CD90).
2.4. Tissue Collection. Rats were anaesthetized by CO
2
after
which blood was collected by cardiac puncture and stored
in heparinized tubes for later analysis. Death was confirmed
by cervical dislocation and the gastrointestinal tract of each
animal was removed, measured, emptied of contents, and
weighed. Segments (2 cm) were removed from the jejunum
and ileum and placed in 10% buffered formalin for histolog-
ical analyses. In addition, segments (4 cm) directly adjacent
to the corresponding histological samples were collected and
snap frozen in liquid nitrogen for biochemical analysis.
2.5. Blood Analysis. Immediately after kill, blood samples
stored on ice were subjected to whole blood analysis via
the Blood Cell Diagnostic System CELL-DYN 3700 (Abbott
Diagnostics). Total white and red blood cells (109/L and
1012/L, resp.), as well as differential white blood cell (WBC)
count (%), white and red cell counts, haemoglobin levels
(g/L), hematocrit (%), mean cell volume (fL), mean cell
haemoglobin (pg), mean corpuscular haemoglobin concen-
tration (g/L), red blood cell (RBC) distribution width (% cell
volume), platelet numbers (109/L), and mean platelet volume
(fL) were quantified by this technique.
2.6. Myeloperoxidase Assay. All tissue samples were stored
at −80∘C, until required for biochemical analyses when
samples were homogenized in 10mM phosphate buffer (pH
6).Myeloperoxidase (MPO) is present in neutrophils and can
be used as an indirect marker of small intestinal inflamma-
tion. MPO activity was measured using previously described
methods [28]. Briefly, samples were centrifuged at 13000 g
for 10 minutes, after which the supernatant was discarded,
and the tissue homogenate was resuspended in 0.5% hex-
adecyltrimethyl ammonium bromide. After vortexing for 2
minutes, samples were recentrifuged, at 5000 g for 2 minutes.
The supernatants were then dispensed into 96-well plates.
After the addition of o-dianisidine, absorbance was read at
450 nm.
2.7. Histology. Intestinal samples were transferred from 10%
buffered formalin into 70% ethanol 24 hours after collection.
Specimens were then routinely processed and embedded
in paraffin wax and 4 𝜇m sections prepared and stained
with hemotoxylin and eosin. Small intestinal crypt depth
and villus height were measured in the jejunum and ileum
(40 villi and 40 crypts per section) [29]. Blinded analyses
of all samples were undertaken using a light microscope
(Olympus BH-2, Tokyo, Japan) and digital camera (Sony,
Tokyo, Japan) and Image Pro-Plus Software Package Version
4.5.1.2.7 (Media Cybernetics, Silver Spring, MD).
2.8. Statistical Analysis. Daily metabolic data, diarrhoea
severity, and SBT data were analysed using a repeated
measures ANOVA and pairwise comparisons made by a
Bonferroni post hoc test with a significance level of 0.05. His-
tological data, MPO, and blood data were analysed by two-
factor (factor 1 = injection type, factor 2 = gavage treatment)
ANOVA with a Bonferroni adjustment and a significance
level of 0.05. Normal data distribution was determined by Q-
Q plots of data sets, and data transformations were applied
as deemed appropriate. All data were expressed as mean ±
standard error of the mean (SEM). Statistical analysis was
conducted using SPSS 15.0.1 for Windows (IBM SPSS).
3. Results
3.1. Extract Composition. Consistent with previous studies
[11, 12, 25, 30], the extract from the hypobranchial glands of
Dicathais orbita was composed of a mixture of brominated
indole derivatives. LC/MS analysis revealed that the domi-
nant compound was tyrindoleninone (36.5%, retention time
11.28min; Figure 1) with a molecular mass of 257, 257 for Br79
and Br81. Another dominant peak at 5.52min corresponds
to tyrindoxyl sulphate (28.9%, Figure 1), with major ions
in ESI-MS at m/z 336, 338. The peak at 6.42min with
major ions in ESI-MS at m/z 224, 226 was attributed to
the molecular mass of the oxidative product 6-bromoisatin
(16.5%, Figure 1), whereas the mass spectrum of the peak at
9.40min with major ions in ESI-MS at m/z 302, 304 was
indicative of the methane thiol adduct tyrindolinone (11.8%,
Figure 1). The smaller peak at 12.07min can be attributed
to the dimer tyriverdin (4.1%, Figure 1), with m/z 511, 513,
515 (for Br79 Br79, Br79 Br81, and Br81 Br81) and major
fragment ions at m/z 417, 419, 421 formed by the elimination
of dimethyl disulphide. A minor peak detected at 14.4min
(0.5%, Figure 1) is consistent with the Tyrian purple pigment
6,6-dibromoindigo and/or 6,6, dibromoindigotin (m/z/417,
419, 421) [25].Theminor peaks at 2.12min are consistent with
the choline ester murexin (1.5%m/z 224, fragment ion at 165)
[9].
3.2. Metabolic Parameters. Following 5FU injection, body-
weight was significantly lower in all 5FU groups compared
to non-5FU controls (Figure 2(a)), consistent with the 5FU
model of intestinal mucositis. Food intake (measured as total
food intake before and after 5FU or saline injection) was
significantly lower in the saline/oil control groups before and













































Figure 1: Liquid chromatograph of the extract from the hypobranchial gland of Dicathais orbita. The absorbance units (AU) are from the
diode array detector at 300 nm.Themajor peaks have been identified by retention time (r.t.) and characteristic mass isotopic clusters for Br79,
Br81; r.t. 5.52min = tyrindoxyl sulphate,m/z = 336, 338; r.t. 6.42min = 6-bromoisatin,m/z 224, 226; r.t. 9.53min = tyrindolinone,m/z = 302,
304; r.t. 11.28min = tyrindoleninone,m/z = 255, 257; and r.t. 12.07min = tyriverdinm/z 511, 513, 517.
after 5FU injection compared to the saline/water control and
snail extract treatment groups (Figure 2(b)). Similarly the
5FU/oil group had significantly lower food intake than the
5FU/water control, before 5FU injection; however, there was
no difference in food intake between saline/oil and all other
groups after 5FU (Figure 2(b)).
There was a moderate increase in diarrhoea severity 72
hours after 5FU injection in all oil treatment groups (1.25),
but not in the 5FU/water group (0.08). Furthermore, muricid
extract alone did not induce diarrhoea in healthy animals, nor
did it increase the severity of diarrhoea in animals injected
with 5FU.
3.3. Intestinal Health and Integrity. The SBT has previously
been validated in rodent models as a surrogate marker
of brush-border sucrase activity, and consequently, small
intestinal integrity and function [27]. Using the SBT, sucrase
activity was measured in vivo as a longitudinal marker
of intestinal function and villous integrity. At the 0 hour
time-point, %CD90 was significantly lower in the sunflower
oil gavage group by 23% and 40% in the saline and 5FU
cohorts respectively, when compared towater gavage controls
(Figure 3).
Histologically, the 5FU rat model of intestinal mucositis
is characterised by villus and crypt atrophy, manifesting
predominantly in the jejunum at 72 hours after 5FU. Accord-
ingly, jejunal villus height was decreased after 5FU injection
(Figure 4(a)) by 31%, 35%, and 35% for the water, LD, and
HD groups, respectively, compared to their corresponding
non-5FU controls (𝑝 < 0.05). Jejunal crypt depth was also
decreased after 5FU by 19%, 29%, and 27% in water, LD
and HD groups, respectively, compared to non-5FU controls
(𝑝 < 0.05). Villus height and crypt depth was significantly
higher in the oil group after 5FU compared to water, LD, and
HD groups. Ileal villus height and crypt depth was similarly
decreased in all groups 72 hours after 5FU compared to non-
5FU controls (Figure 4(b), 𝑝 < 0.05); however, villus height
and crypt depth was significantly higher in the oil group
compared to all other post-5FU groups.
3.4. Immune Parameters. MPO is secreted from activated
neutrophils and small intestinal MPO activity is increased
during 5FU-induced mucositis in rats [29]. In the current
study, jejunal MPO significantly increased in all 5FU groups
compared to their respective saline controls (Figure 5(a)).
Jejunal MPO activity was significantly lower by 34%, 38%,
and 41% in the sunflower oil only group, 72 hours after 5FU
compared to water/5FU, LD/5FU, and HD/5FU, respectively
(𝑝 < 0.05).
Ileal MPO was significantly increased in all groups 72
hours after 5FU compared to their respective saline controls
(Figure 5(b), 𝑝 < 0.05). There was no difference in MPO
activity observed between any of the oil or snail extract



























































Figure 2: Total food intake in rats. (a) All rats receiving 5FU failed to
gain weight after 5FU injection at 0 hr compared to their respective
non-5FU controls. (b) Total food intake was decreased following
5FU injection. Furthermore, total food intakewas significantly lower
(𝑝 < 0.05) before 5FU in the oil/saline and oil/5FU compared
to their respective controls; ∗oil/saline and oil/5FU compared to
water/saline and water/5FU, respectively, #oil/saline compared to
water/saline, LD/saline, and HD/saline, and ∧before 5FU injection
compared to after 5FU injection.
treatment groups, within 5FU or saline injected groups (𝑝 >
0.05).
Whole blood analysis was undertaken to define circu-
lating cell types in blood in response to treatment with
the extract. Lymphocyte numbers were lower by 29%, 23%,
37%, and 39% in the water, sunflower oil, LD, and HD
post-5FU groups, respectively, compared to their saline-only
controls; however, no extract specific response in circulating
lymphocytes was observed in 5FU groups (Figure 6(a)). The























Figure 3: Brush border sucrase activity, measured longitudinally by
sucrose breath test. Sucrase activity was decreased in all groups 72
hours after 5FU injection, indicating reduced intestinal function.
Sucrase activity was significantly lower in the oil only group
compared to all other 5FU groups at the 0-hour time-point. ∗
indicates 𝑝 < 0.05 for oil/5FU compared to all other 5FU groups
at 0 hours.
in response to 5FU injection relative to saline controls but
there was no significant effect of oral gavage treatment.
Conversely, the percent of neutrophils in the blood
tended to increase with 5FU injection relative to saline
injected controls (Figure 6(b)) but there was also a significant
interaction between oral gavage treatment and 5FU injection.
Circulating neutrophils were significantly increased in both
the LD/5FU (425%) and HD/5FU (162%) groups compared
to their respective saline controls (𝑝 < 0.05). Circulating
neutrophils were also increased in the oil/5FU group relative
to saline injected oil gavaged controls (67%); however, this
did not reach statistical significance (𝑝 = 0.058).
4. Discussion
We have previously reported the chemopreventive properties
of muricid extract, originating from Dicathais orbita [12]. In
this study, no intestinal or other peripheral toxicities were
observed when muricid extract was administered by daily
oil gavage to healthy rats for seven days, in the presence
or absence of 5FU. In clinical application, it is possible that
this “nutraceutical” extract could be used in combination
with traditional chemotherapy agents, as an adjunct dietary
supplement, rather than a stand-alone therapy. Existing
chemotherapy regimens, such as 5FU, can be associated
with life-threatening toxicities, particularly gastrointestinal
mucositis [2]. Therefore, identifying novel compounds that
can target tumour cells with no added toxicities is a priority.
The current study found that the combination of the muricid
extract and 5FU in rats resulted in no additional intestinal
toxicity effects.
Body weight and diarrhoea are commonly used clinical
indicators of the extent of intestinal toxicity associated with












































































Figure 4: Small intestinal histology data. (a) Jejunal and (b) ileal villus height (above the 𝑥-axis) and crypt depth (below the 𝑥-axis) in rats
after 5FU injection compared to their respective saline control. ∗ indicates 𝑝 < 0.05 for 5FU groups compared to respective counterpart in





























































Figure 5: Small intestinal MPO activity. (a) Jejunal and (b) ileal sections 72 hours after 5FU injection. ∗ indicates 𝑝 < 0.05 for 5FU groups




















































Figure 6: Blood analysis data. Circulating blood (a) lymphocytes and (b) neutrophils expressed as a percentage of total white blood cells in
rats, 72 hours after 5FU injection relative to saline controls. ∗ indicates 𝑝 < 0.05 for 5FU groups compared to respective control in saline
group.
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cancer therapy regimens. In the current study, muricid
extract alone or in combination with 5FU did not exacerbate
either of these parameters. Furthermore, crypt depth, villus
height, brush border enzyme activity, and intestinal neu-
trophil activity were notmodified in rats treatedwithmuricid
extract alone or in combinationwith 5FU.We have previously
demonstrated a capacity for muricid extract to increase the
crypt cell apoptotic index in the distal colon of mice with
azoxymethane induced colorectal cancer [12]. Consistent
with the current study, no intestinal toxicity effects were
reported, even at the highest dose, suggesting crude muricid
extract could be a safe, nutraceutical option during treatment
regimens for colorectal cancer. However, Westley et al. [24]
reported some mild, idiosyncratic effects on the liver and
gastrointestinal tract after 14 days of oral gavage of muricid
extract, implying further refinement of the composition and
method of administration is still required.
No additional peripheral toxicities were observed in
rats receiving snail extract, suggesting that this combination
of therapies could be used, in an acute setting, with no
detrimental effects. Circulating lymphocytes were decreased
in all groups 72 hours after 5FU injection. In saline injected
rats, there was a small decrease in circulating neutrophils
in both groups receiving muricid extract compared to water
and oil only controls. Although not statistically different,
the decrease in circulating neutrophils suggested that the
muricid extract may have some neutropenic effects. How-
ever, in the 5FU injected rats, muricid extract appears to
increase the number of circulating neutrophils relative to
water and oil controls. The synergistic effect of the extract
treated groups injected with 5FU was statistically significant,
relative to saline injection, suggesting that the extract has
an immunomodulatory effect. A dose dependant increase
in the white blood cells was also observed in mice treated
with 6-bromoisatin for two weeks and then injected with
the carcinogen azoxymethane [31]. Further investigation is
required to define whether 6-bromoisatin in muricid extract
has a direct or indirect effect in lowering and activating
blood neutrophils in the presence and absence of other
chemotherapeutic agents.
Lipid extracts from the related Muricidae gastropod
Rapana venosa have been previously demonstrated to sig-
nificantly improve the healing of induced skin burns in
Wistar rats [32]. Evidence for anti-inflammatory activity was
supported by normal blood cell counts in experimental rats
treated withR. venosa extracts, compared to increasing quan-
tities of leucocytes, lymphocytes, eosinophils, andmonocytes
in the control rats [32]. Although the bioactive brominated
indoles in Muricidae extracts have not been tested for anti-
inflammatory activity, the related metabolite, indirubin, can
suppress the inflammatory response in mice with delayed
type hypersensitivity [20]. Brominated derivatives of indiru-
bin also exhibit inflammatory activity in RAW264.7 cells [33]
and in rat brain microglia [34] and inhibit LPS-stimulated
production of tumor necrosis factor, NF-𝜅B, interleukin-1,
prostaglandin E2 (PEG2), and intracellular reactive oxygen
species [33]. Trace amounts of Tyrian purple pigment were
detected in the extract and 6,6󸀠-dibromoindirubin can be
generated from tyrindoxyl sulphate and 6-bromoisatin in the
presence of oxygen and sunlight. Therefore this compound
may have contributed to some of the observed immune-
modulatory activity. Furthermore, isatin has been found to
inhibit NO production, COX-2, TNF, and PGE2 in mouse
macrophages [35]. Therefore, further investigation of the
immune-modulatory properties of Muricidae extracts and
bioactive compounds in isolation, as well as any synergistic
effects in combination, appears to be warranted.
Partial protection from 5FU-induced intestinal mucositis
was observed in sunflower oil treated rats. This was reflected
by improved villus height and crypt depth measurements in
the jejunum and ileum, as well as lower jejunal MPO activity
compared to all other 5FU groups. Several studies have pre-
viously demonstrated the protective capacity of animal and
plant derived oils using animal models of intestinal damage.
For example, emu oil is derived from the subcutaneous and
retroperitoneal fat of emus and has been used topically for
pain relief and to accelerate wound healing [29]. Recently, a
daily oral gavage of emu oil has shown some efficacy in rat
models of intestinal mucositis and colitis, increasing villus
height and crypt depth, and reducing neutrophil activity
[29, 36]. Similarly, daily oral gavage of Lyprinol, an extract of
theNewZealand green lippedmussel, has demonstrated anti-
inflammatory activity in a mouse model of colitis [37]. Villus
height and crypt depth was also increased in rats consuming
olive oil or maize oil ad libitum in their diets compared to
respective controls [38, 39]. Although no mechanism for the
trophic effects of oils has been delineated, it is clear that
acute, high dose of dietary lipids derived fromplant or animal
origins can stimulate small intestinal growth.
5. Conclusion
In conclusion, the combination of muricid extract with the
cytotoxic chemotherapy agent, 5FU, did not confer any addi-
tional intestinal toxicity, but may have some immunomodu-
latory effects towards neutrophils. Muricid extract has potent
chemopreventive properties and represents a novel func-
tional food for the treatment of colorectal cancer. However,
it is important to completely characterise any potential side-
effects that could be associated with this complementary
nutraceutical. Interestingly, sunflower oil treatment par-
tially protected rats against the intestinal toxicity associated
with 5FU-induced intestinal mucositis and may represent
a broader application of oils to protect against intestinal
mucositis.
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